TY - JOUR
T1 - Emerging technology for early detection and management of postpartum hemorrhage to prevent morbidity
AU - Lord, Megan G.
AU - Calderon, Joaquin A.
AU - Ahmadzia, Homa K.
AU - Pacheco, Luis D.
N1 - Funding Information:
M.G.L. has no financial conflict of interest. M.G.L. is involved in research on the AccuFlow sensor but has no financial relationship with the makers of that device. The AccuFlow sensor is discussed in this manuscript alongside its major competitors. H.K.A.’s research makes use of a rotational thromboelastometry (ROTEM) delta analyzer, which is on loan from the device manufacturer, Instrumentation Laboratory Company, Bedford, Massachusetts. She does not receive any direct funding from the Instrumentation Laboratory Company, and the Instrumentation Laboratory Company is not involved in any way in the design or conduct of her research. The ROTEM delta analyzer is discussed in this manuscript alongside its major commercial competitor (thromboelastography), with equal time spent in the discussion of both products. Furthermore, H.K.A. participated in consulting work for HemoSonics on 1 occasion in the past. No device produced or designed by HemoSonics is discussed in this manuscript.
Publisher Copyright:
© 2022
PY - 2023/2
Y1 - 2023/2
N2 - Despite advances in hemorrhage detection and management, postpartum hemorrhage remains the single leading cause of maternal death worldwide. Within the United States, hemorrhage is the leading cause of maternal death on the day of delivery and within the first week after delivery. Blood transfusion after hemorrhage represents a large proportion of severe maternal morbidity during and after delivery. Blood loss during delivery has historically been assessed visually by inspecting soiled pads, linens, and laparotomy sponges. These methods underestimate the volume of blood loss by as much as 40%, becoming increasingly inaccurate as blood loss increases. Young, healthy obstetrical patients compensate for blood loss via peripheral vasoconstriction, maintaining heart rate and blood pressure in a normal range until over 1 L of blood has been lost. A significant decrease in blood pressure along with marked tachycardia (>120 bpm) may not be seen until 30% to 40% of blood volume has been lost, or 2.0 to 2.6 L in a healthy term pregnant patient, after which the patient may rapidly decompensate. In resource-poor settings especially, the narrow window between the emergence of significant vital sign abnormalities and clinical decompensation may prove catastrophic. Once hemorrhage is detected, decisions regarding blood product transfusion are routinely made on the basis of inaccurate estimates of blood loss, placing patients at risk of underresuscitation (increasing the risk of hemorrhagic shock and end-organ damage) or overresuscitation (increasing the risk of transfusion reaction, fluid overload, and alloimmunization). We will review novel technologies that have emerged to assist both in the early and accurate detection of postpartum hemorrhage and in decisions regarding blood product transfusion.
AB - Despite advances in hemorrhage detection and management, postpartum hemorrhage remains the single leading cause of maternal death worldwide. Within the United States, hemorrhage is the leading cause of maternal death on the day of delivery and within the first week after delivery. Blood transfusion after hemorrhage represents a large proportion of severe maternal morbidity during and after delivery. Blood loss during delivery has historically been assessed visually by inspecting soiled pads, linens, and laparotomy sponges. These methods underestimate the volume of blood loss by as much as 40%, becoming increasingly inaccurate as blood loss increases. Young, healthy obstetrical patients compensate for blood loss via peripheral vasoconstriction, maintaining heart rate and blood pressure in a normal range until over 1 L of blood has been lost. A significant decrease in blood pressure along with marked tachycardia (>120 bpm) may not be seen until 30% to 40% of blood volume has been lost, or 2.0 to 2.6 L in a healthy term pregnant patient, after which the patient may rapidly decompensate. In resource-poor settings especially, the narrow window between the emergence of significant vital sign abnormalities and clinical decompensation may prove catastrophic. Once hemorrhage is detected, decisions regarding blood product transfusion are routinely made on the basis of inaccurate estimates of blood loss, placing patients at risk of underresuscitation (increasing the risk of hemorrhagic shock and end-organ damage) or overresuscitation (increasing the risk of transfusion reaction, fluid overload, and alloimmunization). We will review novel technologies that have emerged to assist both in the early and accurate detection of postpartum hemorrhage and in decisions regarding blood product transfusion.
KW - compensatory reserve
KW - postpartum hemorrhage
KW - postpartum hemorrhage detection
KW - rotational thromboelastometry
KW - thromboelastography
KW - thromboelastometry
KW - viscoelastic hemostasis assays
UR - http://www.scopus.com/inward/record.url?scp=85140355240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140355240&partnerID=8YFLogxK
U2 - 10.1016/j.ajogmf.2022.100742
DO - 10.1016/j.ajogmf.2022.100742
M3 - Review article
C2 - 36075527
AN - SCOPUS:85140355240
SN - 2589-9333
VL - 5
JO - American journal of obstetrics & gynecology MFM
JF - American journal of obstetrics & gynecology MFM
IS - 2
M1 - 100742
ER -